AR027878A1 - Metodos para identificar y utilizar compuestos inhibidores de amiloides - Google Patents

Metodos para identificar y utilizar compuestos inhibidores de amiloides

Info

Publication number
AR027878A1
AR027878A1 ARP000105767A ARP000105767A AR027878A1 AR 027878 A1 AR027878 A1 AR 027878A1 AR P000105767 A ARP000105767 A AR P000105767A AR P000105767 A ARP000105767 A AR P000105767A AR 027878 A1 AR027878 A1 AR 027878A1
Authority
AR
Argentina
Prior art keywords
amiloid
identifying
methods
inhibiting compounds
inhibiting
Prior art date
Application number
ARP000105767A
Other languages
English (en)
Original Assignee
Wyeth Corp
Res Found Mental Hygiene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Res Found Mental Hygiene filed Critical Wyeth Corp
Publication of AR027878A1 publication Critical patent/AR027878A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
ARP000105767A 1999-11-05 2000-11-01 Metodos para identificar y utilizar compuestos inhibidores de amiloides AR027878A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16381999P 1999-11-05 1999-11-05

Publications (1)

Publication Number Publication Date
AR027878A1 true AR027878A1 (es) 2003-04-16

Family

ID=22591720

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105767A AR027878A1 (es) 1999-11-05 2000-11-01 Metodos para identificar y utilizar compuestos inhibidores de amiloides

Country Status (10)

Country Link
US (1) US20080085244A1 (es)
EP (1) EP1272853A2 (es)
JP (2) JP2003522737A (es)
AR (1) AR027878A1 (es)
AU (2) AU779781B2 (es)
CA (1) CA2390161A1 (es)
MX (1) MXPA02004480A (es)
NZ (3) NZ536461A (es)
TW (3) TWI302099B (es)
WO (1) WO2001035106A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524354A (ja) * 2001-03-16 2004-08-12 ワイス エストロゲン補充療法
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP1929291A4 (en) * 2005-09-26 2010-12-22 Univ California ÖSTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATIVE DISEASES AND DISEASES
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
JP3552272B2 (ja) * 1994-05-27 2004-08-11 帝国臓器製薬株式会社 免疫化学的簡易アッセイ方法および装置
EP0937137A4 (en) * 1996-06-06 2002-10-23 Univ Washington PERLECAN EXPRESSIVE TRANSGENIC ANIMALS AND METHOD FOR IDENTIFYING COMPOUNDS FOR TREATING AMYLOIDOSIS
JPH1090261A (ja) * 1996-08-23 1998-04-10 Fuotoreru Patrick 性ステロイドホルモン測定用プレート、これを用いた測定キット及び測定法
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
AU7260398A (en) * 1997-04-28 1998-11-24 University Of British Columbia, The Method and composition for modulating amyloidosis
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Also Published As

Publication number Publication date
US20080085244A1 (en) 2008-04-10
TW200621221A (en) 2006-07-01
CA2390161A1 (en) 2001-05-17
NZ536461A (en) 2005-02-25
AU2005200176A1 (en) 2005-02-10
AU1459201A (en) 2001-06-06
TWI302099B (en) 2008-10-21
JP2003522737A (ja) 2003-07-29
MXPA02004480A (es) 2004-09-10
NZ543850A (en) 2009-03-31
AU2005200176B2 (en) 2007-10-25
WO2001035106A2 (en) 2001-05-17
NZ518780A (en) 2006-02-24
AU779781B2 (en) 2005-02-10
JP2008058329A (ja) 2008-03-13
TW200834074A (en) 2008-08-16
EP1272853A2 (en) 2003-01-08
WO2001035106A3 (en) 2002-11-14
TWI265026B (en) 2006-11-01

Similar Documents

Publication Publication Date Title
PT1181017E (pt) Inibidores de metaloproteases
ATE318603T1 (de) Pyrrolotriazin kinasehemmer
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
DE60107692D1 (de) System zur erfassung von naheliegenden objekten
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
ID23983A (id) Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin
ATE245142T1 (de) No-synthase inhibitoren
PT1066628E (pt) Transportador de registos e aparelho para fazer o varrimento do transportador de registos
PT1194404E (pt) Inibidores de aspartil-protease
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
PT958287E (pt) Inibidores de sulfamida-metaloprotease
NO990113D0 (no) Flerskrog-fart°y
DE69832968D1 (de) Werkzeug zur reibungsminderung
FI980614A0 (fi) Pao funktionstillstaond beroende svaromeddelande
PT1113965E (pt) Acessorio para gargalo de garrafa
NO20021658D0 (no) Asfaltenhemmere
FR2774599B1 (fr) Cataplasme
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
AR027878A1 (es) Metodos para identificar y utilizar compuestos inhibidores de amiloides
ATE225346T1 (de) Fkbp inhibitoren
MA24877A1 (fr) INHIBITEURS DE PROTéASES
ID23196A (id) Gandaran untuk lampuflouresen
NO993161D0 (no) Cyklooksygenaseinhibitor
PT974275E (pt) Proceso para esterilizacao
NO20015827D0 (no) Neuronal död inhibitorer

Legal Events

Date Code Title Description
FB Suspension of granting procedure